Cargando…

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer

INTRODUCTION: The importance of the endothelium in angiogenesis and cancer is undisputed, and its integrity may be assessed by laboratory markers such as circulating endothelial cells (CECs), endothelial progenitor cells (EPCs), plasma von Willebrand factor (vWf), soluble E selectin, vascular endoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramcharan, K S, Lip, G Y H, Stonelake, P S, Blann, A D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453738/ https://www.ncbi.nlm.nih.gov/pubmed/25211664 http://dx.doi.org/10.1038/bjc.2014.491

Ejemplares similares

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
por: Codony-Servat, Jordi, et al.
Publicado: (2017)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer
por: Wang, X, et al.
Publicado: (2014)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
por: Carrasco, J, et al.
Publicado: (2015)

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
por: Fürstenberger, G, et al.
Publicado: (2006)

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies
por: McCoy, M J, et al.
Publicado: (2012)

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
por: Weickhardt, A J, et al.
Publicado: (2015)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells
por: te Velde, E A, et al.
Publicado: (2005)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
por: Dudek, A Z, et al.
Publicado: (2007)

A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer
por: Annaházi, Anita, et al.
Publicado: (2016)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms
por: Amankwatia, E B, et al.
Publicado: (2015)

Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy
por: Fankhauser, Christian Daniel, et al.
Publicado: (2018)

Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy
por: Keidar, M, et al.
Publicado: (2011)

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting
por: Lambrechts, Diether, et al.
Publicado: (2015)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
por: Crozier, J E M, et al.
Publicado: (2006)

Harmonisation of biobanking standards in endometrial cancer research
por: Adishesh, M, et al.
Publicado: (2017)

C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
por: Yamaguchi, K, et al.
Publicado: (2010)

Endothelial apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity
por: Dimitrov, S, et al.
Publicado: (2005)

Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus
por: Makino, T, et al.
Publicado: (2009)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay
por: Zlotnik, Y, et al.
Publicado: (2005)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency
por: Bracht, K, et al.
Publicado: (2010)

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
por: Goede, V, et al.
Publicado: (2010)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_gm46pm0lv90gtithtdfdb59pfb